Malignant hyperthermia, though uncommon, is a serious and life threatening condition. Malignant hyperthermia is an autosomal dominant disorder that affects skeletal muscle. It can be caused by various general anesthetic agents like succinylcholine and several inhaled anesthetics. Malignant hyperthermia is a relevant topic to certified registered nurse anesthetists due to the potentially fatal result if not recognized and treated promptly. In understanding the pathophysiology, risk factors, signs and symptoms, epidemiology, and current treatments the health care provider can help to prevent complications due to this disorder (Nagelhout, 2014)
Malignant Hyperthermia (MH) is a rare, autosomal dominant skeletal muscle disorder that can have an ...
Rethinking Malignant Hyperthermia Protocols In person poster Undergraduate Student: Currie, Kelsey R...
Introduction Malignant Hyperthermia (MH) is an inherited hypermetabolic syndrome triggered by exposu...
According to the Malignant Hyperthermia Association of the United States (2015), “Malignant hyperthe...
Abstract Malignant Hyperthermia (MH) is a rare inherited disorder in which exposure to triggering ag...
Malignant hyperthermia is a subclinical myopathy in which general anesthesia triggers an uncontrolla...
Malignant hyperthermia manifests clinically as a hypermetabolic crisis when a malignant hyperthermia...
Malignant hyperthermia is a serious anesthetic complication, presenting with various manifestations,...
Malignant Hyperthermia (MH) is a rare, hereditary, life-threatening disease triggered by volatile an...
Malignant hyperthermia (MH) is a rare and life-threatening pharmacogenetic disorder triggered by vol...
ObjectivesMalignant hyperthermia susceptibility is an important risk factor during general anesthesi...
Purpose: Malignant hyperthermia is a rare crisis associated with anesthesia that boasts an 80%fatali...
Malignant hyperthermia (MH) is a potentially fatal, inherited disorder of muscle hypermetabolism tha...
Background Malignant hyperthermia (MH), a metabolic myopathy triggered by volatile anesthetics an...
Malignant hyperthermia (MH) can develop after contact with volatile anesthetics (halothane, enfluran...
Malignant Hyperthermia (MH) is a rare, autosomal dominant skeletal muscle disorder that can have an ...
Rethinking Malignant Hyperthermia Protocols In person poster Undergraduate Student: Currie, Kelsey R...
Introduction Malignant Hyperthermia (MH) is an inherited hypermetabolic syndrome triggered by exposu...
According to the Malignant Hyperthermia Association of the United States (2015), “Malignant hyperthe...
Abstract Malignant Hyperthermia (MH) is a rare inherited disorder in which exposure to triggering ag...
Malignant hyperthermia is a subclinical myopathy in which general anesthesia triggers an uncontrolla...
Malignant hyperthermia manifests clinically as a hypermetabolic crisis when a malignant hyperthermia...
Malignant hyperthermia is a serious anesthetic complication, presenting with various manifestations,...
Malignant Hyperthermia (MH) is a rare, hereditary, life-threatening disease triggered by volatile an...
Malignant hyperthermia (MH) is a rare and life-threatening pharmacogenetic disorder triggered by vol...
ObjectivesMalignant hyperthermia susceptibility is an important risk factor during general anesthesi...
Purpose: Malignant hyperthermia is a rare crisis associated with anesthesia that boasts an 80%fatali...
Malignant hyperthermia (MH) is a potentially fatal, inherited disorder of muscle hypermetabolism tha...
Background Malignant hyperthermia (MH), a metabolic myopathy triggered by volatile anesthetics an...
Malignant hyperthermia (MH) can develop after contact with volatile anesthetics (halothane, enfluran...
Malignant Hyperthermia (MH) is a rare, autosomal dominant skeletal muscle disorder that can have an ...
Rethinking Malignant Hyperthermia Protocols In person poster Undergraduate Student: Currie, Kelsey R...
Introduction Malignant Hyperthermia (MH) is an inherited hypermetabolic syndrome triggered by exposu...